Get the Stockscreener App
1.67
6.18%
-0.11
After Hours:
1.67
Neumora Therapeutics Inc Stock (NMRA) Latest News
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: - GlobeNewswire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewswire Inc.
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar
Pharma Co. Misled Investors On Depression Drug, Suit Says - Law360
ROSEN, A RANKED AND LEADING INVESTOR RIGHTS FIRM, - GlobeNewswire
Investor Alert: Robbins LLP Informs Investors of the Neumora Therapeutics, Inc. Class Action - PR Newswire
Financial Metrics Check: Neumora Therapeutics Inc (NMRA)’s Ratios for Trailing Twelve Months - The Dwinnex
NMRA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit First Filed by The Firm - PR Newswire
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - ACCESS Newswire
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces That Neumora Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Neumora Sued After Anti-Depression Drug Trial Results Sank Stock - Bloomberg Law
NMRA INVESTOR ALERT: Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
ForexTV | Small Business Resources - ForexTV.com
NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA - Business Wire
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Update - MarketBeat
RBC Capital Mkts’s latest rating for NMRA stock - Knox Daily
Upward Trajectory: Neumora Therapeutics Inc (NMRA) Posts a Gaine, Closing at 1.93 - The Dwinnex
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Neumora Therapeutics and Other Stocks Suffer Major Losses as Market Faces Declines - HPBL
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $16.50 - Defense World
Neumora Stock Hits Record Low on Depression Drug Study Failure - MSN
Neumora Therapeutics, Inc. Presents Corporate Presentation at J.P. Morgan Healthcare Conference - Defense World
Neumora shares slump after depression drug fails in key trial - MSN
William Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
William Blair Reiterates "Outperform" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals - MSN
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):